Medical Innovation Exchange

After FDA setback, MEI, Kyowa confirm phase 2 efficacy with Japanese blood cancer data drop

https://www.fiercebiotech.com/biotech/after-fda-setback-mei-kyowa-confirm-phase-2-efficacy-japanese-blood-cancer-data-drop

Leave a Comment

Your email address will not be published. Required fields are marked *

Leave the field below empty!